Answers are grounded in this paper and cite their sources.
Pediatric obstructive sleep apnea (OSA) affects up to 5.7% of children and is associated with cardiovascular, growth and neurobehavioral consequences. Adenotonsillectomy remains the first-line treatment, but residual disease is frequent, and pediatric OSA in non-obese children has been framed as a disorder of orofacial growth, drawing orthodontists into its management. This critical narrative review appraises the evidence on rapid maxillary expansion (RME), functional mandibular advancement appliances and adjunctive myofunctional therapy, with attention to quality of life and to public oral health in Brazil. Guidelines, systematic reviews, meta-analyses, randomized controlled trials (RCTs) and landmark cohorts indexed in PubMed up to 2026 were examined. Uncontrolled cohorts reported marked and stable reductions in the apnea-hypopnea index after RME in selected children with isolated maxillary constriction, with normal polysomnography up to 12 years later. However, systematic reviews restricted to controlled evidence found only one RCT comparing RME with watchful waiting, with no significant difference, and a 2026 update identified no new trial with an untreated control arm. Evidence for functional appliances is of very low quality, whereas myofunctional therapy reduced the apnea-hypopnea index by 43% in mild-to-moderate cases. Quality of life is rarely measured in orthodontic studies. Orthodontic and orthopedic treatment should be indicated on dentofacial grounds, integrated into multidisciplinary care and evaluated with polysomnographic and patient-centered outcomes; RME should not be offered as a stand-alone cure. The study's limitations and suggestions for future research are discussed.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: